🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Abbott India Limited ABBOTINDIA NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.abbott.co.in
Company Profile ↓
₹27,525.00
-19.23% 1Y
Mkt Cap₹58,488.70 Cr
P/E37.69
P/B12.19
Div. Yield1.93%
52W High₹35,195.00
52W Low₹25,180.00
Book Value₹2,246.75
EPS (TTM)₹730.36

Company Overview

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 32.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 41.9%.

Consistent Profit Growth

Net profit has compounded at 17.8% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 37.7, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 22.4%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,929.05 Cr (+8.1% YoY); net profit ₹1,552.02 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +8.1%, earnings +9.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.0%, profit CAGR 17.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.03%
1 Year:8.11%

Compounded Profit Growth

5 Years:17.80%
1 Year:9.73%

Stock Price Performance

1 Year:-19.23%
6 Months:-3.01%
3 Months:+6.75%
1 Month:+5.46%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 23% of range
₹25,180.00 ₹35,195.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)65.87 · Neutral
Price Performance
1M+5.46%
3M+6.75%
6M-3.01%
1Y-19.23%
Valuation vs Sector

P/E of 37.69 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 32.5%.
  • Healthy ROCE of 41.9%.
  • Excellent profit margin of 22.4%.
  • Profit CAGR of 17.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
37.69
Industry PE
39.97
Forward P/E
30.42
PEG Ratio
-
Book Value
₹2,246.75
Price to Book
12.19
P/S
8.40
EV/EBITDA
29.34
Dividend Yield
1.93%

Growth (CAGR)

Revenue 5Y
9.03%
Profit 5Y
17.80%
Revenue (YoY)
8.11%
Earnings (YoY)
9.73%

Profitability & Returns

ROCE
41.87%
ROE
32.51%
ROA
23.87%
Profit Margin
22.40%
Op Margin
26.21%
Gross Margin
46.71%
EPS (Latest Qtr)
₹185.85
EPS (TTM)
₹730.36

Balance Sheet & Liquidity

Debt/Equity
3.60
Quick Ratio
1.91
Current Ratio
2.55
Debt
₹171.99 Cr
Total Assets
₹6,501.93 Cr
Current Assets
₹3,770.69 Cr
Working Capital
₹2,294.12 Cr

Ownership

Promoter Holding
75.55%
Chg in Prom Hold
-
FII / Inst Holding
7.91%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹58,488.70 Cr
Total Revenue (TTM)
₹6,929.05 Cr
EBITDA
₹2,180.22 Cr
Free Cash Flow
₹1,278.32 Cr
Operating Cash Flow
₹1,319.24 Cr
Shares Outstanding
₹2.12 Cr
Gross Margin
46.71%
Payout Ratio
65.04%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA 27,525.00 37.69 ₹58,488.70 Cr 1.93% 41.87% 32.51% 9.03% 17.80%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,604.59 Cr1,738.35 Cr1,757.15 Cr1,724.04 Cr1,709.51 Cr
Cost of Revenue 855.96 Cr942.12 Cr936.85 Cr908.81 Cr905.04 Cr
Gross Profit 748.63 Cr796.23 Cr820.30 Cr815.23 Cr804.47 Cr
Operating Expenses 338.02 Cr370.12 Cr336.77 Cr370.53 Cr342.69 Cr
Operating Income 410.61 Cr426.11 Cr483.53 Cr444.70 Cr461.78 Cr
EBITDA 504.56 Cr518.43 Cr572.12 Cr533.23 Cr556.44 Cr
Interest Expense 3.92 Cr5.82 Cr7.55 Cr5.48 Cr6.14 Cr
Pretax Income 482.71 Cr493.13 Cr545.93 Cr508.98 Cr531.23 Cr
Tax Provision 115.67 Cr127.27 Cr130.66 Cr133.02 Cr136.30 Cr
Net Income 367.04 Cr365.86 Cr415.27 Cr375.96 Cr394.93 Cr
Diluted EPS 172.72172.17195.42176.92185.85

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -5,346.73 Cr5,847.19 Cr6,409.15 Cr6,929.05 Cr
Cost of Revenue -2,983.97 Cr3,232.35 Cr3,496.78 Cr3,692.82 Cr
Gross Profit -2,362.76 Cr2,614.84 Cr2,912.37 Cr3,236.23 Cr
Operating Expenses -1,215.49 Cr1,209.30 Cr1,289.57 Cr1,420.11 Cr
Operating Income -1,147.27 Cr1,405.54 Cr1,622.80 Cr1,816.12 Cr
EBITDA -1,359.78 Cr1,701.37 Cr1,970.18 Cr2,180.22 Cr
Interest Expense -15.99 Cr12.45 Cr11.43 Cr24.99 Cr
Pretax Income -1,273.82 Cr1,617.75 Cr1,886.95 Cr2,079.27 Cr
Tax Provision -324.41 Cr416.53 Cr472.51 Cr527.25 Cr
Net Income -949.41 Cr1,201.22 Cr1,414.44 Cr1,552.02 Cr
Diluted EPS -446.78565.28665.62730.36

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -4,555.51 Cr5,193.49 Cr5,917.31 Cr6,501.93 Cr
Current Assets -3,025.11 Cr3,245.84 Cr4,765.11 Cr3,770.69 Cr
Cash & Equivalents -239.67 Cr291.74 Cr560.59 Cr442.33 Cr
Inventory -648.85 Cr619.58 Cr882.04 Cr947.26 Cr
Receivables -318.80 Cr319.11 Cr380.23 Cr361.73 Cr
Total Liabilities -1,366.97 Cr1,494.60 Cr1,684.16 Cr1,727.74 Cr
Current Liabilities -1,206.02 Cr1,342.72 Cr1,407.19 Cr1,476.57 Cr
Long Term Debt -----
Total Debt -113.17 Cr83.23 Cr196.67 Cr171.99 Cr
Total Equity -3,188.54 Cr3,698.89 Cr4,233.15 Cr4,774.19 Cr
Shares Outstanding -2.12 Cr2.12 Cr2.12 Cr2.12 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -893.39 Cr1,212.81 Cr1,011.84 Cr1,319.24 Cr
Investing Cash Flow --147.71 Cr-416.03 Cr182.18 Cr-371.38 Cr
Financing Cash Flow --638.72 Cr-744.71 Cr-925.17 Cr-1,066.12 Cr
Capital Expenditure --34.11 Cr-48.33 Cr-52.60 Cr-40.92 Cr
Free Cash Flow -859.28 Cr1,164.48 Cr959.24 Cr1,278.32 Cr
Net Change in Cash -106.96 Cr52.07 Cr268.85 Cr-118.26 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -44.2%44.7%45.4%46.7%
Operating Margin % -21.5%24.0%25.3%26.2%
Net Margin % -17.8%20.5%22.1%22.4%
ROE % -29.8%32.5%33.4%32.5%
ROCE % -34.3%36.5%36.0%36.1%

Shareholding Pattern

Insiders
75.55%
Institutions
7.91%
Public Float
32.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABBOTINDIA

Google News Fri, 10 Jul 2026

Abbott India Limited Actuals & Estimates (NSE:ABBOTINDIA) - TradingView

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQbk9nWkNKTVdxeU1GbDlCU1ZjLU1lcFBwS3E2aWtZWUdQejBYWmZ2SHU5YzVKSEtabm0zaHJ6Ym9LNnlwRmJ5cTREM0VrOHB6dUNzU1pRdjJpQmFnZ0xINDFyT2VVeTN5YWw0YUowSGtocG9nRm9YNURGa2NnSkpDeDdqTUszb19VQ1E?oc…

Google News Wed, 24 Dec 2025

Abbott India Limited (NSE:ABBOTINDIA) stock most popular amongst public companies who own 75%, while individual investors hold 17% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOb3poWUFqR05nOUNCMFpJNzd4RFQ5Smd4LVNnSlFiNm5KRjAzY0JVbXp2M1Q3czJTVkNXSmJlR0ZtemFwcVRZRUt3OUg1d0FqZFNnQ19qejVweksyUXZ6SlU2ZUM0U1d0Nk10NS02a0VlcU5xNmdhT1lFekNOdVlVQWY1ZTFXaHFLMXVCUH…

Google News Fri, 10 Jul 2026

ABBOTINDIA Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9uSVRBVGJ0bzctcHlhdzJTS2ZJZG1La2ttbThkMklxYzJTMXlJY001T1ZpT1VrQWZxVGFzSW1lSEI2QlZVOUdmT1NxZkxCb3dGOFVueUwyX3hUVnRXNUtyQ1czUER6b2JUR29JOS1R?oc=5" target="_blank">ABBOTINDIA Outlook …

Google News hu, 25 Jun 2026

ABBOTINDIA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9FMWRMZHZYLXltOERCUmdqSEtxWGRpcGlMY2czSGt1ZGxZU1Y5d0lubWRhal9ZRU92M29HQ0dLUVl0bEZnSW9WVW9YOGZZSEFSREtuSk1md1lVUmVnMlBBcE5OakNZdFkxelZvSW5GYl9nQ281UzRydF9Ec2IyZw?oc=5" target="_blan…

Google News Mon, 19 Jan 2026

Getting In Cheap On Abbott India Limited (NSE:ABBOTINDIA) Is Unlikely - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNYVpYSDZjS2dPR3hzVGUtNEJfaTVqNGkzYWNpNmNSYUxWZHczSmpLenpHanZOVkpMQWpYT0xmWUFFY0ZTbENYZWFFRWRicnYxZ0NhbjFRSjBaN3g1THphZ3dMVGg2NlUyd2FQbHRwQWNfci1PZE1jVWxsbFhVWG42TFYxUjdsT2NKWE1OSE…

Google News Mon, 24 Nov 2025

Abbott India Limited's (NSE:ABBOTINDIA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNeTMwTDV5eHlrSzRscUo1VlNxNEdvZTJKdGFQd2J0VU1nckJrQ0VlU2hxWVdQaW00SFpFNGUwVnZ5eDZ6X1FaWDVoNHp5STFHU04yQU82VWREaDcxSGhYUkhpSFgwOEE1SzVhUUlZZWVSNTFJejRJelFoTU4zVVdadzUwQ1lvZ1RUX2ZHUV…

ABBOTINDIA — Frequently Asked Questions

What is the current share price of Abbott India Limited (ABBOTINDIA)?

As of 2026-07-15 09:52 IST, Abbott India Limited (ABBOTINDIA) trades at ₹27,525.00 on NSE. Its 52-week range is ₹25,180.00 to ₹35,195.00.

What is the market capitalisation of ABBOTINDIA?

Abbott India Limited (ABBOTINDIA) has a market capitalisation of ₹58,488.70 Cr on NSE.

What is the P/E ratio of ABBOTINDIA?

ABBOTINDIA trades at a trailing price-to-earnings (P/E) ratio of 37.69. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 12.19.

Does ABBOTINDIA pay a dividend?

Abbott India Limited (ABBOTINDIA) currently offers a dividend yield of 1.93%.

What is the return on equity (ROE) of ABBOTINDIA?

ABBOTINDIA has a return on equity (ROE) of 32.51%. Its return on capital employed (ROCE) is 41.87%.

Is ABBOTINDIA a good stock to buy?

This page provides a data-driven analysis of Abbott India Limited (ABBOTINDIA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space